

IMMUNOGEN INC  
Form 8-K  
May 17, 2004

[QuickLinks](#) -- Click here to rapidly navigate through this document

---

---

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

### FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

---

Date of Report (Date of earliest event reported): **May 17, 2004**

### ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

**Massachusetts**  
(State or other jurisdiction  
of incorporation)

**0-17999**  
(Commission  
File Number)

**04-2726691**  
(IRS Employer  
Identification No.)

**128 Sidney Street, Cambridge, MA 02139**  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(617) 995-2500**

(Former name or former address, if changed since last report)

---

---

---

**Item 5. Other Events.**

On May 17, 2004, ImmunoGen, Inc. announced that Shire BioChem Inc. intends to sell the 4,096,098 shares of ImmunoGen common stock held by it. The press release announcing this event is incorporated herein by reference and filed as Exhibit 99.1 hereto.

**Item 7. Financial Statements and Exhibits.**

(c)  
Exhibits.

<b>Exhibit No.</b>	<b>Exhibit</b>
99.1	Press Release of ImmunoGen, Inc. dated May 17, 2004

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ImmunoGen, Inc.**  
(Registrant)

Date: May 17, 2004

/s/ VIRGINIA A. LAVERY

---

Virginia A. Lavery  
Vice President, Finance and Treasurer

3

---

QuickLinks

[Item 5. Other Events.](#)

[Item 7. Financial Statements and Exhibits.](#)

[SIGNATURES](#)